Here, we present a relapsed Ph+ ALL patient who underwent allo-SCT and two separate CD19-targeted CAR T-cell therapies pre- and post-transplant, and this patient experienced multiple relapses in spite of a deep response to all the salvage therapies. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.